Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 9
2014 9
2015 8
2016 3
2017 3
2018 6
2019 7
2020 3
2021 4
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Lozano-Rabella M, et al. Among authors: martin liberal j. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265. doi: 10.1158/1078-0432.CCR-22-3298. Clin Cancer Res. 2023. PMID: 36749875 Free PMC article.
The expanding role of immunotherapy.
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. Martin-Liberal J, et al. Cancer Treat Rev. 2017 Mar;54:74-86. doi: 10.1016/j.ctrv.2017.01.008. Epub 2017 Feb 11. Cancer Treat Rev. 2017. PMID: 28231560 Review.
New drugs in sarcomas.
Martin-Liberal J, Benson C, Judson I. Martin-Liberal J, et al. Expert Opin Pharmacother. 2014 Feb;15(2):221-9. doi: 10.1517/14656566.2014.865015. Epub 2013 Nov 25. Expert Opin Pharmacother. 2014. PMID: 24266804 Review.
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Drakaki A, et al. Among authors: martin liberal j. Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. Clin Cancer Res. 2023. PMID: 37651261 Clinical Trial.
Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J, Kordbacheh T, Larkin J. Martin-Liberal J, et al. Expert Opin Drug Saf. 2015 Jun;14(6):957-64. doi: 10.1517/14740338.2015.1021774. Epub 2015 Apr 30. Expert Opin Drug Saf. 2015. PMID: 25927979 Review.
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.
Soto-Castillo JJ, Llavata-Marti L, Fort-Culillas R, Andreu-Cobo P, Moreno R, Codony C, García Del Muro X, Alemany R, Piulats JM, Martin-Liberal J. Soto-Castillo JJ, et al. Among authors: martin liberal j. Int J Mol Sci. 2023 Jul 6;24(13):11143. doi: 10.3390/ijms241311143. Int J Mol Sci. 2023. PMID: 37446319 Free PMC article. Review.
Targeting protein kinase C in sarcoma.
Martin-Liberal J, Cameron AJ, Claus J, Judson IR, Parker PJ, Linch M. Martin-Liberal J, et al. Biochim Biophys Acta. 2014 Dec;1846(2):547-59. doi: 10.1016/j.bbcan.2014.10.002. Epub 2014 Oct 16. Biochim Biophys Acta. 2014. PMID: 25453364 Review.
62 results